Exercise
OtherAfter placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
NCT Number: NCT04663217
This study aims to investigate the exercise profile in pulmonary hypertension patients with either pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension or pulmonary hypertension due to left heart disease and in disease control.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Kerckhoff-Klinik, Bad Nauheim, Hesse, Germany
This is a dual-center observational prospective study in patients with pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, pulmonary hypertension due to left heart disease. Patients undergoing right heart catheterisation due to dyspnoe with invasive exclusion of pulmonary hypertension will be recruited as disease control.
The study comprises a 1-day screening period, followed by a right heart catheterization with exercise challenge.
The study starts with screening, information of the patients and Informed Consent Form signature at day -1. Screening and inclusion of the patient can be performed on the same day. On the day of the planned right heart catheterization based on clinical grounds, exercise right heart catheterisation (RHC) using Swan-Ganz and/or Conductance catheters with simultaneous echocardiography will be performed. End of study is defined as a complete exercise RHC. Adverse events will be assessed until 1 day after the exercise RHC.
After placement of the Swan-ganz or Conductance catheter patients will undergo an exercise challenge using the following protocol in semi-supine position until exhaustion:
Simultaneously, echocardiography and lung ultrasound will be performed before exercise (baseline), after 6 minutes of exercise and at maximum.
After assessment of right ventriclure pressure-volume loops during maximum exercise, guided by echocardiographic the conductance catheter will be placed in the right atrium to obtain right atrium pressure-volume loops during maximum exercise.
Optional, the exercise RHC will be performed without the Conductance catheter and only with the Swan-Ganz catheter. In this case, pressure values and cardiac output will be measured using the thermodilution method, averaging 3-5 measurements at baseline, 6 minutes and maximum. Detailed assessment of right atrial pressure curves (with a and v wave) will be performed at baseline, 6 minutes and maximum exercise.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Time frame: 1 day
mean pulmonary arterial pressure (mmHg)
Time frame: 1 day
cardiac output (l/min);
Time frame: 1 day
pulmonary arterial wedge pressure (mmHg)
Time frame: 1 day
arterial elastance (mmHg/mL)
Time frame: 1 day
end-systolic elastance (mmHg/mL)
Time frame: 1 day
mean right atrial pressure (mmHg)
Time frame: 1 day
right atrial strain (%)
Time frame: 1 day
right ventricular volume (ml)
Time frame: 1 day
right ventricular strain (%)
Time frame: 1 day
atrial volume to pressure ratio (ml/mmHg)
Time frame: 1 day
B-Lines
Time frame: 1 day
left atrial strain (%)
Time frame: 1 day
left atrial volume (ml)
Time frame: 1 day
diameter inferior vena cava (mm)
University of Giessen
Other
Acronym: EXERTION
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03626688
Cardiovascular Diseases, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04732221
Cardiovascular Diseases, Hypertension
La Jolla, California, United States
View Trial DetailsNCT03754660
Cardiovascular Diseases, Hypertension
Graz, Austria
View Trial DetailsNCT02825160
Cardiovascular Diseases, Hypertension
Multiple Locations, Japan
View Trial Details